Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12858MR)

This product GTTS-WQ12858MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12858MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7482MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ13488MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ13674MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ15262MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ12909MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ4448MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12036MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ1574MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW